Recent advances in enzyme engineering and design have expanded nature's catalytic repertoire to functions that are new to biology [1] [2] [3] . However, only a subset of these engineered enzymes can function in living systems [4] [5] [6] [7] . Finding enzymatic pathways that form chemical bonds that are not found in biology is particularly difficult in the cellular environment, as this depends on the discovery not only of new enzyme activities, but also of reagents that are both sufficiently reactive for the desired transformation and stable in vivo. Here we report the discovery, evolution and generalization of a fully genetically encoded platform for producing chiral organoboranes in bacteria. Escherichia coli cells harbouring wildtype cytochrome c from Rhodothermus marinus 8 (Rma cyt c) were found to form carbon-boron bonds in the presence of borane-Lewis base complexes, through carbene insertion into boron-hydrogen bonds. Directed evolution of Rma cyt c in the bacterial catalyst provided access to 16 novel chiral organoboranes. The catalyst is suitable for gram-scale biosynthesis, providing up to 15,300 turnovers, a turnover frequency of 6,100 h -1 , a 99:1 enantiomeric ratio and 100% chemoselectivity. The enantiopreference of the biocatalyst could also be tuned to provide either enantiomer of the organoborane products. Evolved in the context of whole-cell catalysts, the proteins were more active in the whole-cell system than in purified forms. This study establishes a DNA-encoded and readily engineered bacterial platform for borylation; engineering can be accomplished at a pace that rivals the development of chemical synthetic methods, with the ability to achieve turnovers that are two orders of magnitude (over 400-fold) greater than those of known chiral catalysts for the same class of transformation [9] [10] [11] 
. Although this non-enzymatic method for capturing boron is sufficient for the survival of an organism, it is limited by the inherent affinity of a substrate towards boric acid, and lacks tunability and generality for synthetic biology applications. Moreover, organisms that produce organoboranes (compounds that contain carbon-boron bonds) are unknown.
We envisioned that enzyme-catalysed borylation could provide living organisms with the ability to produce boron-containing products tailored to our needs. Such an enzyme is not known in nature, but we hypothesized that existing natural proteins might be repurposed and engineered to perform this task. In the past, we and others have exploited the promiscuity of natural and engineered haem proteins for various non-natural reactions 4, 6, 7, 17 . The resulting enzymes are fully genetically encoded and carry out their synthetic functions in their bacterial expression hosts. Here, we focused on introducing boron motifs to organic molecules enantioselectively, as this would generate boron-containing carbon stereocentres, which are important structural features in functional organoboranes such as the US Food and Drug Administration (FDA)-approved chemotherapeutics Velcade and Ninlaro 18 . They are also versatile precursors for chemical derivatization through stereospecific carbon-boron to carbon-carbon or carbonheteroatom bond conversion [19] [20] [21] . Although boron reagents applicable for carbon-boron bond formation in water are known 22, 23 , their biocompatibility, cell permeability, stability and reactivity in living systems, which contain an abundance of biomolecules, nucleic acids and metal ions, are uncertain. Nevertheless, as boron reagents designed for in vivo chemical biology applications are precedented [24] [25] [26] , we reasoned that reagents suitable for biological borylation could be found. We identified borane-Lewis base complexes as potential candidates owing to their aqueous stability and reactivity towards carbenoid B-H insertion [9] [10] [11] 27 (Extended Data Fig. 2 ), a mechanistic pathway we thought could be adapted for use in the biological environment owing to its orthogonality to the existing biochemistry of living systems.
We first set out to assess whether biological organoborane production might be feasible in a bacterial cell. E. coli BL21(DE3) cells harbouring wild-type cytochrome c from the Gram-negative, thermohalophilic bacterium Rhodothermus marinus 8 (Rma cyt c) were incubated with N-heterocyclic carbene borane 28, 29 (NHC-borane) 1 and ethyl 2-diazopropanoate (Me-EDA) 2 in neutral buffer (M9-N minimal medium, pH 7.4). After incubation at room temperature, in vivo production of organoborane 3 was observed, with 120 turnovers (calculated with respect to the concentration of Rma cyt c expressed in E. coli, Fig. 1a , b) and an enantiomeric ratio (e.r.) of 85:15 (R/S isomer = 6, Fig. 1c ). Because the pET22b/pEC86 expression system translocates Rma cyt c to the E. coli periplasm for post-translational maturation (during which the haem cofactor is covalently ligated to the cyt c apoprotein) 30 , we assumed that borylation takes place in the periplasmic compartment. In the absence of Rma cyt c, E. coli yielded only a trace amount of borylation product with very low stereoselectivity (Extended Data Table 1 ). Both the substrates and the organoborane product were stable under these conditions. The haem cofactor alone could also promote the borylation reaction, although with no stereoselectivity. Other cytochrome c proteins, cytochromes P450, and globins also demonstrated carbon-boron bond-forming ability, but their selectivities were unsatisfactory (Extended Data Table 1) .
To improve the performance of this whole-cell catalyst, we subjected the wild-type Rma cyt c (hereafter referred to as BOR WT ) to sitesaturation mutagenesis, sequentially targeting active-site amino acid residues M100, V75 and M103, which are closest to the haem iron in BOR WT (within 7 Å, Fig. 1d ). Each single-site site-saturation mutagenesis library was cloned using the 22c-trick method as whole-cell catalysts in 96-well plates for improved borylation enantioselectivity, and the best variant was used to parent the next round of mutation and screening. With a single mutation M100D replacing the distal axial ligand, the first-generation biocatalyst exhibited a 16-fold improvement in turnover compared with the wild type (total turnover number (TTN) 1,850, Fig. 1b) , with 88:12 e.r. (R/S isomer = 7; Fig. 1c ). The M100D mutation also substantially improved carbene transfer reactivity for Si-H insertion catalysed by Rma cyt c 6 . This improvement in catalytic performance is probably due to the removal of the axial ligand from the haem iron, which opens a site primed for iron carbenoid formation and subsequent product formation 32 . Two subsequent rounds of mutagenesis and screening led to variant BOR R1 (V75R M100D M103T), which exhibited a turnover of 2,490 and an e.r. of 97.5:2.5 (R/S isomer = 39). This genetically programmed biological function is readily scalable from an analytical to a millimolar scale, with 0.5 mmol substrates, BOR R1 produced organoborane 3 in 97.5:2.5 e.r. and 75% isolated yield, with a TTN of 3,000. The absolute configuration of product 3 was unambiguously assigned as R by X-ray crystallography.
With an excellent borylating bacterium in hand, the properties and potential of the system were assessed. We characterized the initial rates of in vivo borylation and found that screening for improved enantioselectivity also led to an overall rate enhancement: whole-cell BOR R1 is 15 times faster than BOR WT , with a turnover frequency of 6,100 h -1 . Notably, as purified protein or in cell lysate, both BOR
R1
and BOR WT are orders of magnitude slower than in vivo (Fig. 1e) . When isolated BOR R1 protein and whole-cell BOR R1 were preincubated with Me-EDA 2 before the borylation reaction, the isolated Figure 1 | Discovery, evolution and characterization of a bacterial catalyst for borylation. a, Reaction scheme shows a representative in vivo borylation reaction between NHC-borane 1 and diazo ester 2 to yield organoborane 3. Standard substrate loading is 10 mM for both 1 and 2. The absolute configuration of biosynthesized 3 was assigned as R by X-ray crystallography. b, c, Sequential site-saturation mutagenesis of Rma cyt c targeting active-site amino acid residues M100, V75 and M103 improved the turnover (b) and enantioselectivity (c) of bacterial production of organoborane 3. Whole-cell Rma cyt c variants were compared using E. coli cells with an optical density at 600 nm (OD 600 ) of 15. Total turnover numbers (TTNs) were calculated with respect to the concentration of Rma cyt c expressed in E. coli and represent the total number of turnovers obtained from the catalyst under the stated reaction conditions. d, X-ray crystal structure of wild-type Rma cyt c (PDB: 3CP5). e, Turnover frequencies (h −1 , on log scale) of BOR WT and BOR R1 as whole-cell catalysts, cell lysates, or purified proteins for the production of organoborane 3. f, Purified and whole-cell BOR R1 were preincubated with NHC-borane 1, Me-EDA 2, or organoborane 3 before they were used as borylation catalysts to determine the inactivation effects of 1-3. The numbers shown represent the %TTN retained after preincubation, and are relative to a control (no incubation) of the same type of catalyst (purified protein or whole cell). Bars and numbers above bars represent mean values averaged over four biological replicates. Individual data points are shown as overlays. BSA, bovine serum albumin; NHC, N-heterocyclic carbene.
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protein retained only around 50% of its activity, whereas whole-cell BOR R1 retained greater than 90% activity (Fig. 1f ). NHC-borane 1 and organoborane product 3 did not inactivate the enzyme. Me-EDA probably inactivates BOR R1 through carbene transfer to the haem cofactor and/or the nucleophilic side chains of the protein, a mechanism we studied previously in detail for a cytochrome P450-based carbene transferase 33 . The intact periplasm apparently protects BOR R1 from inactivation by Me-EDA, and carbene transfer to yield the organoborane product is generally faster than protein inactivation pathway(s) under those conditions. Similar observations have been reported for other protein-based carbene transfer reaction systems 7, 34 . Analysis of colony-forming units shows that in vivo organoborane production does not markedly reduce the viability of the E. coli (Extended Data Fig. 3 ).
Next, we explored the scope of boron reagents that could function in the cellular environment. Ten boron reagents were tested under turnover-optimized conditions: although the size, solubility and lipophilicity of these reagents varied, all were found to permeate the cell membrane and give the desired products with excellent selectivities and turnovers (Fig. 2a) . Various substitutions on the NHC nitrogen are tolerated (3) (4) (5) (6) (7) (8) (9) (10) . The reaction is chemoselective in the presence of terminal olefins (5), which could function as a reaction handle suitable for downstream biological or bio-orthogonal derivatization. Sterically more demanding tetra-and penta-substituted NHCs are also accepted (7-10). As well as imidazole-based boron reagents, triazolylidene borane and picoline borane could also be used for in vivo borylation, yielding products 11 and 12 in 1,070 TTN and 2,440 TTN, respectively, with uniformly high selectivities (96:4 e.r.). On the gram scale, in vivo borylation produced 740 mg of picoline organoborane 12 with 2,910 TTN, 96:4 e.r. and 42% isolated yield (64% based on recovered starting material, Fig. 2b ). The absolute configuration of 12 was assigned as R by X-ray crystallography. When substrates were added portion-wise at regular time intervals to E. coli expressing BOR R1 (we tested the sequential addition of up to eight equivalents of substrates over a period of 12 h, Fig. 2c ; Extended Data Table 2 ), organoborane 3 was produced with 10,400 turnovers (50% yield, 96:4 e.r.), whereas organoborane 9 was obtained with 15,300 turnovers (73% yield, 96:4 e.r.). No substantial loss in activity or enantioselectivity was observed, demonstrating the potential of this bacterial catalyst for biosynthesis and incorporation into natural or engineered metabolic pathways.
Systematic modification of the diazo ester substituents from Et to Me, i-Pr or Bn revealed that the borylation ability of BOR R1 is not limited to Me-EDA (3, 13-15, Fig. 2d ). The relative insensitivity of the protein to the steric bulk of the ester might indicate that, in the putative iron carbenoid intermediate, this moiety is solvent-exposed rather than embedded within the active site. By re-randomizing the 103 position in BOR R1 , a residue we thought might modulate loop dynamics for improved binding of this substrate, the borylation turnover of 15 improved (from 2,560 to 4,200 TTN) using the triple-mutant V75R/M100D/M103D (BOR R2 , Fig. 3a) . From the same site-saturation library, a borylation catalyst for trifluoromethyl-substituted diazo ester (CF 3 -EDA) was also discovered (V75R/M100D/M103F, BOR R3 ). Acceptor-acceptor diazo reagents such as CF 3 -EDA are less reactive towards carbenoid formation because of their electron-deficient nature and have not been used before this for enzymatic carbene-transfer reactions. The present system tolerates this class of substrates and yielded product 16 with 95:5 e.r. and 1,560 TTN.
To further broaden the generality of this borylation platform, we re-examined the evolutionary landscape from BOR WT to BOR R1 to search for promiscuous mutants that might unlock new reactivities. Double mutant V75P/M100D (BOR P* ) stood out as highly productive but poorly selective (69:31 e.r.) for Me-EDA borylation in the M100D/V75X site-saturation library. As proline-mediated helix kinks are known to induce structural and dynamic changes to proteins, we asked whether the V75P mutation might provide access to a unique reaction space. Ethyl 2-diazophenylacetate (Ph-EDA) is a bulky donoracceptor diazo reagent inactive towards BOR WT , but when added to E. coli harbouring BOR P* with NHC-borane 1, Ph-EDA was transformed to organoborane 17 in 100 TTN and 75:25 e.r. (Fig. 3a) . By accumulating three additional loop mutations though directed evolution (M99Y, T101A and M103F, Extended Data ) for the borylation of Ph-EDA, supporting 340 turnovers with an e.r. of 94:6. BOR P* also allows us to move beyond diazo ester-based substrates and apply bacterial production to a different class of chiral organoboranes: although inactive towards BOR WT , CF 3 -substituted (diazomethyl)benzene (CF 3 -DMB) reacted with NHC-borane 1 in the presence of BOR P* to yield organoborane (R)-18 in vivo with 74 turnovers and modest selectivity (79:21 e.r.). We enhanced this through three cysteine mutations at Y71, M89 and M99 (BOR P2 , Extended Data Table 3 ) to produce organoborane (R)-18 in 96:4 e.r. and 1,010 TTN. Through X-ray crystallography, the absolute configuration of (R)-18 was unambiguously assigned.
Finally, we asked whether the stereochemical preference of biological borylation could be switched. Towards this end, examination of the M100D V75X site-saturation library for CF 3 -DMB borylation led us to identify a variant (V75G M100D; BOR G* ) having an inverted stereochemical preference to BOR P* in the carbon-boron bondforming step (31:69 e.r. for R/S isomer; 340 TTN). The selectivity of BOR G* was further tuned through mutations M89F, T98V, M99L, T101L and M103F (BOR G1 , Extended Data Table 3 ) to yield organoborane (S)-18 with 90:10 e.r. and 1,120 TTN.
Chiral α -trifluoromethylated organoboranes are useful synthetic building blocks that combine the unique properties of fluorinated motifs with the versatile synthetic applications of organoboranes 35 . However, methods for their asymmetric preparation are rare 11, 36 . Our ability to biosynthesize both enantiomers of these molecules may have applications in pharmaceutical and agrochemical synthesis. For example, product (R)-18 was converted to pinacol boronate 19 with retention of the stereogenic carbon centre (Fig. 3b) . Through wellestablished stereospecific transformations [19] [20] [21] , pinacol boronates can be diversified into a broad array of chiral compounds. We demonstrated the transformation of 19 to alcohol 20, a motif found in compounds useful for the treatment of cancer 37 and neurodegenerative diseases 38 , and the Matteson homologation-oxidation product 21, both of which were obtained with good stereocontrol.
In conclusion, we present a platform for biological borylation, which can be tuned and configured through DNA manipulation. Microorganisms are powerful alternatives to chemical methods for producing pharmaceuticals, agrochemicals, materials and fuels. They are available by fermentation on a large scale and at low cost, and their genetically encoded synthetic abilities can be systematically modified and optimized. Borylation chemistry can now be added to the vast synthetic repertoire of biology. 
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Detailed experimental methods are available in the Supplementary Information. Data reporting. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Materials. Plasmid pET22b(+ ) was used as a cloning vector, and cloning was performed using Gibson assembly 39 . The cytochrome c maturation plasmid pEC86 30 was used as part of a two-plasmid system to express prokaryotic cytochrome c proteins. Cells were grown using Luria-Bertani medium or HyperBroth (AthenaES) with 100 μ g ml −1 ampicillin and 20 μ g ml −1 chloramphenicol (LB amp/chlor or HB amp/chlor ). Cells without the pEC86 plasmid were grown with 100 μ g ml −1 ampicillin (LB amp or HB amp ). Electrocompetent E. coli cells were prepared following a published protocol 40 . T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New England Biolabs (NEB). M9-N minimal medium (abbreviated as M9-N buffer; pH 7.4) was used as a buffering system for whole cells, lysates and purified proteins unless otherwise specified. M9-N buffer was used without a carbon source; it contains 47.7 mM Na 2 HPO 4 , 22.0 mM KH 2 PO 4 , 8.6 mM NaCl, 2.0 mM MgSO 4 and 0.1 mM CaCl 2 . Plasmid construction. All variants described in this paper were cloned and expressed using the pET22b(+ ) vector (Novagen). The gene encoding Rma cyt c (UniProt ID B3FQS5) was obtained as a single gBlock (IDT), codon-optimized for E. coli, and cloned using Gibson assembly 39 into pET22b(+ ) (Novagen) between restriction sites NdeI and XhoI in frame with an N-terminal pelB leader sequence (to ensure periplasmic localization and proper maturation; MKYLLPTAAAGLLLLAAQPAMA) and a C-terminal 6× His-tag. This plasmid was co-transformed with the cytochrome c maturation plasmid pEC86 into E. cloni EXPRESS BL21(DE3) cells (Lucigen). Cytochrome c expression and purification. Purified cytochrome c proteins were prepared as follows. One litre HB amp/chlor in a 4 l flask was inoculated with an overnight culture (20 ml, LB amp/chlor ) of recombinant E. cloni EXPRESS BL21(DE3) cells containing a pET22b(+ ) plasmid encoding the cytochrome c variant, and the pEC86 plasmid. The culture was shaken at 37 °C and 200 rpm (no humidity control) until the OD 600 was 0.7 (approximately 3 h). The culture was placed on ice for 30 min, and isopropyl β -D-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic acid (ALA) were added to final concentrations of 20 μ M and 200 μ M, respectively. The incubator temperature was reduced to 20 °C, and the culture was shaken for 22 h at 200 rpm. Cells were collected by centrifugation (4000g, 15 min, 4 °C), and the cell pellet was stored at − 20 °C until further use (at least 24 h). The cell pellet was resuspended in buffer containing 100 mM NaCl, 20 mM imidazole, and 20 mM Tris-HCl buffer (pH 7.5 at 25 °C) and cells were lysed by sonication (2 min, 2 s on, 2 s off, 40% duty cycle; Qsonica Q500 sonicator). Cell debris was removed by centrifugation for 20 min (5,000g, 4 °C). Supernatant was sterile-filtered through a 0.45 μ m cellulose acetate filter and purified using a 1 ml Ni-NTA column (HisTrap HP, GE Healthcare) using an AKTA purifier FPLC system (GE Healthcare). The cytochrome c protein was eluted from the column by running a gradient from 20 to 500 mM imidazole over 10 column volumes. The purity of the collected cytochrome c fractions was analysed using SDS-PAGE. Pure fractions were pooled and concentrated using a 3 kDa molecular weight cut-off centrifugal filter and dialysed overnight into 0.05 M phosphate buffer (pH = 7.5) using 3 kDa molecular weight cut-off dialysis tubing. The dialysed protein was concentrated again, flash-frozen on dry ice, and stored at − 20 °C. The concentration of cytochrome c was determined in triplicate using the haemochrome assay described below. Cytochrome P450 and globin expression and purification. Purified P450s and globins were prepared differently from the cytochrome c proteins, and described as follows. One litre HB amp in a 4 l flask was inoculated with an overnight culture (20 ml, LB amp ) of recombinant E. cloni EXPRESS BL21(DE3) cells containing a pET22b(+ ) plasmid encoding the P450 or globin variant. The culture was shaken at 37 °C and 200 rpm (no humidity control) until the OD 600 was 0.7 (approximately 3 h). The culture was placed on ice for 30 min, and IPTG and ALA were added to final concentrations of 0.5 mM and 1 mM, respectively. The incubator temperature was reduced to 20 °C, and the culture was shaken for 20 h at 200 rpm. Cells were collected by centrifugation (4 °C, 15 min, 4,000g), and the cell pellet was stored at − 20 °C until further use (at least 24 h). The cell pellet was resuspended in buffer containing 100 mM NaCl, 20 mM imidazole, and 20 mM Tris-HCl buffer (pH 7.5 at 25 °C). Haemin (30 mg ml −1 , 0.1 M NaOH; Frontier Scientific) was added to the resuspended cells such that 1 mg of haemin was added for every 1 g of cell pellet. Cells were lysed by sonication (2 min, 1 s on, 2 s off, 40% duty cycle; Qsonica Q500 sonicator). Cell debris was removed by centrifugation for 20 min (27,000g, 4 °C). Supernatant was sterile-filtered through a 0.45 μ m cellulose acetate filter, and purified using a 1 ml Ni-NTA column (HisTrap HP, GE Healthcare) using an AKTA purifier FPLC system (GE healthcare). The P450 and globin proteins were eluted from the column by running a gradient from 20 mM to 500 mM imidazole over 10 column volumes. The purity of the collected protein fractions was analysed using SDS-PAGE. Pure fractions were pooled and concentrated using a 10 kDa molecular weight cut-off centrifugal filter and buffer-exchanged with 0.1 M phosphate buffer (pH = 8.0). The purified protein was flash-frozen on dry ice and stored at − 20 °C. P450 and globin concentrations were determined in triplicate using published extinction coefficients and the haemochrome assay described below. Haemochrome assay. A solution of sodium dithionite (10 mg ml −1 ) was prepared in M9-N buffer. Separately, a solution of 1 M NaOH (0.4 ml) was mixed with pyridine (1 ml), followed by centrifugation (10,000g, 30 s) to separate the excess aqueous layer to give a pyridine-NaOH solution. To a cuvette containing 700 μ l protein solution (purified protein or heat-treated lysate) in M9-N buffer, 50 μ l of dithionite solution and 250 μ l pyridine-NaOH solution were added. The cuvette was sealed with Parafilm, and the UV-Vis spectrum was recorded immediately. Cytochrome c concentration was determined using ε 550-535 = 22.1 mM
Protein concentrations determined by the haemochrome assay were in agreement with those determined by the bicinchoninic acid assay (Thermo Fisher) using BSA for standard curve preparation. Mutagenesis library construction. Cytochrome c site-saturation mutagenesis libraries were generated using a modified version of the 22-codon site-saturation method 31 . For each site-saturation library, oligonucleotides were ordered such that the coding strand contained the degenerate codon NDT, VHG or TGG. The reverse complements of these primers were also ordered. The three forward primers were mixed together in a 12:9:1 ratio, (NDT:VHG:TGG) and the three reverse primers were mixed similarly. Two PCRs were performed, pairing the mixture of forward primers with a pET22b(+ ) internal reverse primer, and the mixture of reverse primers with a pET22b(+ ) internal forward primer. The two PCR products were gel-purified, ligated together using Gibson assembly 39 , and transformed into E. cloni EXPRESS BL21(DE3) cells. Mutagenesis library screening in whole cells. Single colonies were picked with toothpicks off of LB amp/chlor agar plates, and grown in deep-well (2 ml) 96-well plates containing LB amp/chlor (400 μ l) at 37 °C, 250 rpm shaking, and 80% relative humidity overnight. After 16 h, 30 μ l aliquots of these overnight cultures were transferred to deep-well 96-well plates containing HB amp/chlor (1 ml) using a 12-channel EDP3-Plus 5-50 μ l pipette (Rainin). Glycerol stocks of the libraries were prepared by mixing cells in LB amp/chlor (100 μ l) with 50% v/v glycerol (100 μ l). Glycerol stocks were stored at − 78 °C in 96-well microplates. Growth plates were shaken for 3 h at 37 °C at 250 rpm, and 80% relative humidity. The plates were then placed on ice for 30 min. Cultures were induced by adding 10 μ l of a solution, prepared in sterile deionized water, containing 2 mM IPTG and 20 mM ALA. The incubator temperature was reduced to 20 °C, and the induced cultures were shaken for 20 h (250 rpm, no humidity control). Cells were pelleted (4,000g, 5 min, 4 °C), resuspended in 380 μ l M9-N buffer, and the plates containing the cell suspensions were transferred to an anaerobic chamber. To deep-well plates of cell suspensions were added NHC-borane substrate (10 μ l per well, 400 mM in MeCN) and diazo reagent (10 μ l per well, 400 mM in MeCN). The plates were sealed with aluminium sealing tape, removed from the anaerobic chamber, and shaken at 500 rpm for 6 h (24 h for reactions with Ph-EDA or CF 3 -DMB because of their lower aqueous solubility). After quenching with hexanes:ethyl acetate (4:6 v/v, 0.6 ml), internal standard was added (20 μ l of 20 mM 1,2,3-trimethoxybenzene in toluene). The plates were then sealed with sealing mats and shaken vigorously to thoroughly mix the organic and aqueous layers. The plates were centrifuged (4,000g, 5 min) and the organic layer (200 μ l) was transferred to autosampler vials with vial inserts for gas chromatography-mass spectrometry (GC-MS) or chiral high performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) analysis. Hits from library screening were confirmed by small-scale biocatalytic reactions. Cell lysate preparation. Cell lysates were prepared as follows: E. coli cells expressing Rma cyt c variant were pelleted (4,000g, 5 min, 4 °C), resuspended in M9-N buffer and adjusted to the appropriate OD 600 . Cells were lysed by sonication (2 min, 1 s on, 2 s off, 40% duty cycle; Qsonica Q500 sonicator), aliquoted into 2 ml microcentrifuge tubes, and the cell debris was removed by centrifugation for 10 min (14,000g, 4 °C). The supernatant was sterile-filtered through a 0.45 μ m cellulose acetate filter, and the concentration of cytochrome c protein lysate was determined using the haemochrome assay. Using this protocol, the protein concentrations we typically observed for OD 600 = 15 lysates were in the 8-15 μ M range for wild-type Rma cyt c and 1-10 μ M for other Rma cyt c variants. Small-scale whole-cell bioconversion. In an anaerobic chamber, NHC-borane (10 μ l, 400 mM in MeCN) and diazo reagent (10 μ l, 400 mM in MeCN) were added to E. coli harbouring Rma cyt c variant (380 μ l, adjusted to the appropriate OD 600 ) in a 2 ml crimp vial. The vial was crimp-sealed, removed from the anaerobic chamber, and shaken at 500 rpm at room temperature for 6 h (24 h for reactions 
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